Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma × avelumab × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 21 Carcinoma, Transitional Cell 14 Neoplasms 12 Ovarian Neoplasms 11 Carcinoma, Merkel Cell 11 Urinary Bladder Neoplasms 10 Carcinoma, Renal Cell 10 Squamous Cell Carcinoma of Head and Neck 8 Neoplasm Metastasis 7 Colorectal Neoplasms 7 Triple Negative Breast Neoplasms 5 Stomach Neoplasms 5 Pancreatic Neoplasms 5 Recurrence 4 Melanoma 4 Breast Neoplasms 4 Uterine Cervical Neoplasms 2 Kidney Neoplasms 2 Kidney Diseases 2 Head and Neck Neoplasms 2 Fallopian Tube Neoplasms 2 Central Nervous System Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Hepatocellular 2 Urothelial Cancer 1 Urologic Neoplasms 1 Turcot syndrome 1 Small Cell Lung Carcinoma 1 Sarcoma 1

Interventions

Carboplatin 28 pembrolizumab 21 Paclitaxel 20 Cisplatin 20 Pemetrexed 17 Gemcitabine 10 durvalumab 9 Nivolumab 9 osimertinib 8 130-nm albumin-bound paclitaxel 8 Everolimus 7 Docetaxel 7 Sunitinib 6 Sorafenib 6 Fluorouracil 5 Cetuximab 5 Axitinib 5 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5 volociximab 4 trebananib 4 cabozantinib 4 atezolizumab 4 Radiotherapy 4 reolysin 3 liposomal doxorubicin 3 lenvatinib 3 epothilone B 3 catumaxomab 3 brigatinib 3 Trastuzumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03268057 2022-05-02

CLASSICAL-Lung

Vaccinex Inc.

Phase 1/2 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡